Island Pharmaceuticals Ltd, a company listed on the Australian Securities Exchange under the ticker ILA, has achieved a significant milestone in its efforts to combat dengue fever and other mosquito-borne diseases. The company has successfully dosed the third cohort of participants in its single ascending dose study under fasted conditions for ISLA-101, a promising drug candidate. This achievement follows the approval from the data safety review committee, which deemed ISLA-101 safe and tolerable after it was administered to 16 subjects across the first two cohorts.

The single ascending dose study is a crucial part of Island Pharmaceuticals’ research, aiming to establish the safety of ISLA-101 and its efficacy in achieving blood concentrations capable of combating the dengue virus. Having dosed all eight subjects in the third cohort, the company moves forward, pending the review of the results from this phase.

The next step in this scientific journey involves the group that received the highest safe dose undergoing a final round of dosing, but under fed conditions this time. This process is carefully monitored to ensure the safety of the participants while progressing towards a solution for dengue fever.

Under the leadership of CEO Dr. David Foster, Island Pharmaceuticals is on track to report the trial data in early 2024. This study, serving as a precursor to the Phase 2a PEACH clinical trial, is a beacon of hope in the fight against mosquito-borne diseases. With each milestone achieved, the potential for a future where dengue fever is treatable and preventable becomes increasingly tangible.